<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="iso-abbrev">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="publisher-id">Medicina Oral S.L.</journal-id><journal-title-group><journal-title>Medicina Oral, Patolog&#x000ed;a Oral y Cirug&#x000ed;a Bucal</journal-title></journal-title-group><issn pub-type="ppub">1698-4447</issn><issn pub-type="epub">1698-6946</issn><publisher><publisher-name>Medicina Oral S.L.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39954281</article-id><article-id pub-id-type="pmc">PMC11972648</article-id>
<article-id pub-id-type="publisher-id">26809</article-id><article-id pub-id-type="doi">10.4317/medoral.26809</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject><subj-group><subject>Oral Medicine and Pathology</subject></subj-group></subj-group></article-categories><title-group><article-title>Minimally invasive treatment of benign oral vascular lesions: A retrospective study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Silva</surname><given-names>Herberth Campos</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Teles</surname><given-names>Ana Cl&#x000e1;udia Oliveira</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rocha</surname><given-names>Gabriela Fonseca</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>da Silveira</surname><given-names>Esmeralda Maria</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Douglas-de-Oliveira</surname><given-names>Dhelfeson Willya</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mesquita</surname><given-names>Ana Terezinha Marques</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Dentistry, Faculty of Biological and Health Sciences, Federal University of the Jequitinhonha and Mucuri Valleys, Diamantina, Minas Gerais, Brazil</aff><author-notes><corresp> Department of Dentistry
Federal University of the Jequitinhonha and Mucuri Valleys
Gloria street, 187, Diamantina, 39.100-000, Minas Gerais, Brazil
, E-mail: <email>herberth.campos@ufvjm.edu.br</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>e217</fpage><lpage>e223</lpage><history><date date-type="accepted"><day>16</day><month>12</month><year>2024</year></date><date date-type="received"><day>11</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2025 Medicina Oral S.L.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background </title><p> The ethanolamine oleate (EO) in different concentrations has been used in sclerotherapy of oral benign vascular lesions (OBVLs). The aim of the present study was to define demographic and clinical characteristics of patients with OBVLs treated with 5% EO.</p></sec><sec><title>Material and Methods </title><p> A retrospective study was conducted of cases treated by sclerotherapy from 1992 to 2022, and medical records of 52 patients with OBVLs were analysed. Thus, 44 cases with complete data were selected and described. Categorical data were analyzed using the chi-square test, with the significance level set at 5% (<italic>p</italic> &#x0003c; 0.05).</p></sec><sec><title>Results </title><p> Mean age was 52.89 years (range seven to 82 years). The female sex was predominant (77%) and brown was the most common skin color (54%). Most lesions occurred on the lower lip (65.9%), tongue (11.4%), buccal mucosa (9.1%), upper lip (6.8%) and palate (25%.3%). Approximately 73% of the lesions were &#x02264; 1 cm, &#x0003e; 1 &#x02264; 2 cm (18.2%,) and &#x0003e; 2 cm (9.1%). Complete regression of the lesions occurred in 97.7% of the cases, with no case of recurrence and no need for complementary surgery. All patients were satisfied with the treatment.</p></sec><sec><title>Conclusions </title><p> Sclerotherapy with 5% EO is a safe and effective method for the treatment of OBVLs.</p><p><bold> Key words:</bold>Hemangioma, vascular malformations, sclerotherapy, ethanolamine oleate.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Hemangioma and vascular malformations are benign vascular lesions that are common in the head and neck region. The International Society for the Study of Vascular Anomalies classifies vascular anomalies as proliferative vascular lesions and non-proliferative vascular malformations (<xref rid="B1" ref-type="bibr">1</xref>). This lesions appears as a red, purplish-red or purplish spot, nodule or papule, depending on the degree of congestion and depth of the lesion in the tissue, with higher incidence in the female sex, individuals with white skin color and premature newborns (<xref rid="B2" ref-type="bibr">2</xref>). In most cases, these lesions are not present at birth, develop in three phases (proliferation, involution and involuted) and tend to have a firm, rubbery consistency and well-defined limits (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Vascular malformations (VMs) can occur in arteries, veins and/or capillaries, are considered structural anomalies of embryonic development, affect both females and males, and the incidence in the head and neck region ranges from 14% to 65% (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B6" ref-type="bibr">6</xref>). VMs are characterized as a defect in the maturation of the vessels and vascular morphogenesis caused mainly by the dysregulation of the pathways of embryogenesis and vasculogenesis (<xref rid="B7" ref-type="bibr">7</xref>), and are divided into two groups: low and high flow. Low flow VMs consist of a venous, capillary or lymphatic component, whereas high-flow VMs consist of an arterial or arteriovenous component (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). Clinically, VMs are similar to hemangioma, but are always present at birth growing with the physical development of the individual, remaining sTable after the growth phase, and do not regress spontaneously (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Age is a predisposing factor in oral varicosities (VOs), which are often found in individuals older than 60 years of age. VOs are acquired variations of normality characterized by a long, abnormal vein with loosening of the tissue, and increase in venous pressure. Oral varicosities are the most common type and appear as single or multiple bluish-purple papules or nodules on the ventrolateral border of the tongue. VOs can also occur at lower frequencies on the lips and other regions of the oral mucosa, and may require interventions in some cases (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>The diagnosis of oral benign vascular lesion (OBVL) is based on the clinical history, physical examination and imaging methods when necessary (<xref rid="B9" ref-type="bibr">9</xref>). Diascopy is an important auxiliary procedure in the establishment of the differential diagnosis (<xref rid="B11" ref-type="bibr">11</xref>). The compression of the glass slide momentarily blanches the lesion and diminishes the size due to vascular emptying, with the subsequent return to it original volume after the removal of the slide, thus excluding the hypotheses of pigmented lesions (<xref rid="B3" ref-type="bibr">3</xref>). Aspiration of the lesion contributes to the diagnosis and determination of the hemodynamics (high-flow or low-flow lesion), which is an important factor in the choice of the ideal treatment (<xref rid="B12" ref-type="bibr">12</xref>). Indications for interventions in cases of OBVL include esthetic problems, pain, ulcerations, tissue deformation, difficulties with regards to psychosocial relationships and the compression of vital organs with the impairment of function (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>The most widely used treatments for OBVLs are sclerotherapy, isolated surgery or surgery combined with sclerotherapy, systemic corticosteroids, interferon-&#x003b1;, cryotherapy, radiotherapy, embolization and laser therapy. Sclerotherapy stands out among the different therapeutic options (<xref rid="B2" ref-type="bibr">2</xref>), and consists of the intralesional injection of sclerosing agents, causing inflammation in the vessels, followed by vascular occlusion and sclerosis resulting in the regression of the lesion (<xref rid="B14" ref-type="bibr">14</xref>). This conservative, noninvasive, low-cost method is effective and does not pose a risk of hemorrhage (<xref rid="B15" ref-type="bibr">15</xref>). The different sclerosing agents described in the literature include ethanolamine oleate (EO), absolute ethanol, sodium tetradecyl sulfate and polidocanol (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>When choosing a sclerosing agent, one must be attentive to its effectiveness, local toxicity, ease of administration and satisfactory results. EO meets these criteria for the treatment of OBVLs (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>), and is one of the safest and most readily available sclerosing agents. EO is considered effective for the treatment of localized vascular lesions in different regions of the body, including the oral cavity (<xref rid="B17" ref-type="bibr">17</xref>). EO is a salt of an unsaturated fatty acid that serves as a sclerosing agent, causing irritation followed by an inflammatory response and fibrosis in the endothelium. It also crosses the vascular wall, causes an extravascular inflammatory response and results in venous sclerosis (<xref rid="B18" ref-type="bibr">18</xref>). The oleic acid portion produces inflammation and can activate clotting through the activity of factor XII, which is also known as Hageman factor (<xref rid="B2" ref-type="bibr">2</xref>). The ethanolamine portion inhibits the formation of the fibrin clot by the chelation of calcium (<xref rid="B18" ref-type="bibr">18</xref>). So, through this mechanism the EO promotes the regression of the lesion replacing the vascular tissue with fibrosis (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Sclerotherapy with 5% EO is a minimally invasive treatment compared to other methods, which are much more invasive and have both greater risks and higher costs. The lower number of appointments, predicTable results and the possibility of performing the procedure in an outpatient clinic makes sclerotherapy with 5% EO an excellent treatment option for OBVLs (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B17" ref-type="bibr">17</xref>).</p><p>The aims of this study were to perform a retrospective analysis of OBVLs treated with sclerotherapy using the intralesional injection of 5% EO, define the demographic characteristics of the patients, identify clinical aspects of OBVLs, side effects and the need or non-need for complementary surgery. In addition, assess the effectiveness of the method and investigate the degree of patient satisfaction with treatment contributing to the establishment of a well-defined, predicTable treatment protocol for OBVLs.</p></sec><sec><title>Material and Methods</title><p>The present study was conducted in accordance with the ethical precepts stipulated in the Declaration of Helsinki, and received approval from the Human Research Ethics Committee of Federal University of the Jequitinhonha and Mucuri Valleys (UFVJM) (approval certificate number: 5.960.085). A retrospective study was conducted using data from the records of patients treated at the UFVJM Stomatology Clinic with the diagnosis of OBVLs treated with sclerotherapy in the period from 1992 to 2022. All records selected had a clinical diagnosis of hemangioma, oral vascular malformations or oral varicosities. Records with incomplete data and cases with other types of treatment were excluded. The demographic variables of interest were age, sex and skin color. Data were also collected on the lesion site, size of the lesion, quantity of sclerosing agent used throughout treatment, number of applications, interval of weeks between applications, classification of pain, side effects and adverse effects. Other data of interest were the complete or non-complete regression of the lesion, the need or non-need for complementary surgical treatment, the recurrence or non-recurrence of the lesion, and patient satisfaction with treatment.</p><p>The protocol for the treatment of OBVLs was sclerotherapy with an intralesional injection of 5% EO (Ethamolin&#x000ae;, Zest Pharma Ltda., Rio de Janeiro, RJ). The patients were previously informed about the treatment as well as possible discomfort and side effects during and after the administration of the medication. Patients who agreed to the procedures signed a statement of informed consent. Lesion size was measured prior to the administration of the medication. The dose of the sclerosing agent was calculated based on the size of the lesion. For lesions less than 1 cm, up to 0.3 mL of 5% EO was applied at a single injection point. For larger lesions, up to 0.3 mL was applied at three injection points for better distribution of the medication. One mL of 5% EO was slowly applied to the periphery of the lesion with the aid of an insulin syringe. An analgesic was prescribed for two days in case of pain. The return appointment was scheduled for 14 days after the procedure for the assessment of the regression of the lesion (size was measured before, during and after treatment) and the assessment of the need or non-need for further applications of 5% EO. Data on sclerotherapy were recorded on a specific form.</p><p>Lesion size was the dependent variable, for which three categories were considered: &#x02264; 1 cm; &#x0003e; 1 and &#x02264; 2 cm; and &#x0003e; 2 cm. The independent variables were the final volume of sclerosing agent, number of applications, interval between applications, side effects, regression of the lesion, need for complementary surgery, comorbidities, recurrence of the lesion and patient satisfaction with treatment.</p><p>For statistical analysis, the results were organized in a database, with the coding, entering and editing of the data. Data were analyzed with the aid of the Statistical Package for the Social Sciences (SPSS&#x000ae;, version 25). Descriptive statistics was performed for the calculation of absolute and relative frequencies. Categorical data were analyzed using the chi-square test, with the significance level set at 5% (<italic>p</italic> &#x0003c; 0.05).</p></sec><sec><title>Results</title><p>A total of 6,668 patient records from the study period (1992 to 2022) were analyzed. Among these, 52 cases of OBVLs were selected and sclerotherapy was the treatment of choice in 44 patients. Average age was 52.89 years (range: seven to 82 years) and women predominated (n = 34; 77.3%) over men (n = 10; 22.3%). In terms of skin color, the majority of the patients were brown (n = 24; 54.5%), followed by white (n = 14; 31.8%) and black (n = 6; 13.6%). Most lesions were on the lower lip (n = 29; 65.9%), followed by the tongue (n = 5; 11.4%), buccal mucosa (n = 4, 9.1%) and upper lip (n = 3; 6.8). Lesion sizes were &#x02264; 1 cm (n = 32; 72.7%), &#x0003e; 1 cm and &#x02264; 2 cm (n = 8; 18.2%) and &#x0003e; 2 cm (n = 4; 9.1%) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>The analysis of the amount of sclerosing agent used throughout treatment for lesion regression revealed that 0.3 mL was satisfactory in 23 cases (52.3%), amounts from &#x0003e; 0.5 mL to &#x02264; 1 mL were used in 11 cases (25.0%), amounts from &#x0003e; 0.3 mL to &#x02264; 0.5 mL were used in seven cases (15.9%) and amounts greater than 1.0 mL were required in three cases (6.8%). A positive correlation was found between lesion size and the amount of sclerosing agent used in the treatments (<italic>p</italic> = 0.030). Two applications of EO were sufficient in most cases (n = 16; 36.5%), one and three applications were sufficient in 11 cases each (50.0%) and four, five or six applications were necessary in two cases each (13.5%). The time between applications of the sclerosing agent was two weeks in 27 cases (61.4%), four or more weeks in 13 cases (29.5%) and three weeks in four cases (9.1%). A positive correlation was found between the number of applications and lesion size (<italic>p</italic> = 0.022; <xref rid="T2" ref-type="table">Table 2</xref>).</p><p>Side effects were reported in 37 cases (84.1%), the most common of which was pain (n = 34; 77.3%), followed by a burning sensation (n = 20; 45.5%), bleeding (n = 13; 29.5%) and ulceration (n = 3; 6.8%). Some patients reported more than one side effect. Mild pain was the most common (n = 14; 31.8%), followed by severe pain (n = 11; 25.0%) and no pain (n = 8; 18.2%). No patient reported unbearable pain. No statistically significant correlation was found between pain and lesion size (<italic>p</italic> = 0.270; <xref rid="T2" ref-type="table">Table 2</xref>).</p><p>Complete regression of the lesions occurred in 43 cases (97.7%), as illustrated in the Fig. <xref rid="F1" ref-type="fig">1</xref>, Fig. <xref rid="F2" ref-type="fig">2</xref> and Fig. <xref rid="F3" ref-type="fig">3</xref>; while partial regression occurred in only one case (2.3%). No statistically significant correlation was found between regression (complete or partial) and lesion size (<italic>p</italic> = 0.825). No case of recurrence was found, and there was no need for complementary surgery (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p>
<fig position="float" id="F1"><label>Figure 1</label><caption><p>Female patient, 62 years old, with a vascular lesion on the lower lip present for 2 years. A: Initial clinical appearance of the lesion. B: Intralesional application of EO. C: Final clinical appearance showing complete regression of the lesion after a single application of 5% EO.</p></caption><graphic xlink:href="medoral-30-e217-g001" position="float"/></fig>
</p><p>
<fig position="float" id="F2"><label>Figure 2</label><caption><p>Male patient, 8 years old, with a congenital vascular lesion on the lower lip. A: Initial clinical appearance of the lesion. B: Final clinical appearance showing complete regression of the lesion after six applications of 5% EO.</p></caption><graphic xlink:href="medoral-30-e217-g002" position="float"/></fig>
</p><p>
<fig position="float" id="F3"><label>Figure 3</label><caption><p>Male patient, 68 years old, with a vascular lesion on the tongue present for 5 years. A: Initial clinical appearance of the lesion. B: Final clinical appearance showing complete regression of the lesion after three applications of 5% EO.</p></caption><graphic xlink:href="medoral-30-e217-g003" position="float"/></fig>
</p></sec><sec><title>Discussion</title><p>Most studies on OBVLs do not clinically differentiate hemangioma and oral vascular malformations or only classify oral vascular malformations as a histological type of hemangioma denominated arteriovenous hemangioma (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B19" ref-type="bibr">19</xref>). In the present study, 95% of cases were clinically diagnosed as hemangiomas or vascular malformations, similar to results reported by Fernandes <italic>et al</italic>. (<xref rid="B15" ref-type="bibr">15</xref>), and differs from reports in other studies that describe a high percentage of lesions classified as oral varicosities (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B19" ref-type="bibr">19</xref>). This divergence in epidemiological data remains to this day, even with the classification proposed by Mulliken and Glowack (<xref rid="B8" ref-type="bibr">8</xref>), and its acceptance by the International Society for the Study of Vascular Anomalies since 1996. The similarity in the clinical characteristics of hemangiomas and vascular malformations makes the diagnosis difficult. Despite this epidemiological divergence in the literature, the classification of these lesions does not affect the planning and proper treatment of the patients (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>).</p><p>In the present study, OBVLs were identified in seven-year-old children up to 82-year-old individuals and the mean age was 52.89 years. Similar findings have been described in previous studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B15" ref-type="bibr">15</xref>). The predominance of the female sex (77.3% of cases) is in agreement with data described in other studies (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18</xref>). In terms of skin color, most patients were brown or white (54% and 31%, respectivelly). In contrast, other studies found a predominance of Caucasians (<xref rid="B15" ref-type="bibr">15</xref>) or individuals of African descent (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>The location of the lesion is a relevant characteristic when defining ideal treatment, as the esthetic factor is a common complaint among patients due to psychosocial discomfort and difficulties in interpersonal relationships (<xref rid="B23" ref-type="bibr">23</xref>). In the present study, the most common site of the lesions was the lips, with 29 cases on the lower lip and three cases on the upper lip, which together accounted for 73% of the cases of OBVLs. These results are similar to findings in previous studies (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B22" ref-type="bibr">22</xref>). However, other study reported that the tongue was the most affected site (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Most of the lesions were &#x02264; 1 cm, similar to other studies (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B22" ref-type="bibr">22</xref>). When treated with 5% EO, satisfactory results were achieved with a small dose of the medication in cases of smaller lesions (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B24" ref-type="bibr">24</xref>). In the present study, the average number of applications per patient was 2.41, which is lower than the 3.07 applications per treatment with concentrations of 1.25% and 2.5% described in a previous study (<xref rid="B2" ref-type="bibr">2</xref>). Kato <italic>et al</italic> . (<xref rid="B17" ref-type="bibr">17</xref>) demonstrated that a concentration of 5% EO requires a smaller volume and lower number of applications compared to concentrations of 1.25% and 2.5%. The reduction in the number of applications favors a shorter treatment time and consequently lowers the possibility of patients withdraw from treatment (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). The present results in terms of the volume and number of applications of 5% EO were similar to those described in previous studies that also used this same concentration (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Although sclerotherapy is one of the most advantageous treatments, the concentration of the sclerosing agent, dose and administration mode are not standardized in the literature (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B21" ref-type="bibr">21</xref>). Although EO is widely used for the treatment of vascular lesions in other parts of the body, further studies on the treatment of such lesions in the oral cavity are needed. Moreover, most studies published consist of case reports involving different sclerosing agents with different concentrations (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B25" ref-type="bibr">25</xref>).</p><p>The 5% EO can cause systemic side effects, such as an anaphylactic reaction and renal toxicity associated with hemolysis and intravascular hemoglobinuria (<xref rid="B26" ref-type="bibr">26</xref>). Local side effects include ulcers and necrosis (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). These effects occur when the administration of 5% EO is performed directly into the surrounding connective tissue or when vascular leakage occurs due to excessive injection pressure (<xref rid="B6" ref-type="bibr">6</xref>). Therefore, slow injection into the lesion is essential to successful treatment with 5% EO (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B15" ref-type="bibr">15</xref>). The margin of safety and reduction of risk is ensured with 1 mL of 5% EO (<xref rid="B27" ref-type="bibr">27</xref>). In the present study, we used a dose greater than 1.0 mL on larger lesions in only three cases (6.8%) and no systemic side effects or necrosis were observed.</p><p>The option for intervention or follow-up depends on the patient&#x02019;s age, lesion size and site (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B6" ref-type="bibr">6</xref>) and more than one technique may be necessary for the treatment of vascular lesions (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B15" ref-type="bibr">15</xref>). Laser therapy is indicated for smaller lesions and may cause atrophy in the skin, temporary or permanent hyperpigmentation, mild skin depression or scars (<xref rid="B16" ref-type="bibr">16</xref>). Embolization requires sophisticated methods, and is not possible in some cases (<xref rid="B3" ref-type="bibr">3</xref>). Surgery can eliminate the lesion, but cannot be performed on all vascular lesions, such as broad diffuse hemangiomas, or in locations of difficult access (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B15" ref-type="bibr">15</xref>). Besides being expensive, surgery poses risks, takes more time and may even require admission to hospital (<xref rid="B28" ref-type="bibr">28</xref>). Sclerotherapy is simple, fast and easy to execute, has good tolerability and low cost and can be performed in a dental office (<xref rid="B24" ref-type="bibr">24</xref>). In the present study, complete regression of the lesion was achieved in 97.7% (n = 43) of cases, which is compatible with findings described in previous studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B24" ref-type="bibr">24</xref>), making surgery, when necessary, only for the removal of the residual fibrotic tissue and phleboliths (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B16" ref-type="bibr">16</xref>). In the present study, complementary surgery was not required in any of the cases. The literature reports that the possibility of complications and side effects cannot be discarded or overlooked (<xref rid="B29" ref-type="bibr">29</xref>). Such complications depend on the quality and quantity of the sclerosing agent, lesion size and experience of the clinician (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B30" ref-type="bibr">30</xref>).</p><p>There is no consensus in the literature on the EO administration procedure performed with or without anesthesia (<xref rid="B22" ref-type="bibr">22</xref>). Most patients in the present study reported some degree of pain (77.3%) during the procedure without anesthesia irrespective of lesion size (<xref rid="T1" ref-type="table">Table 1</xref>). Other reported side effects were a burning sensation, bleeding and ulceration in 54% (n = 24), 29% (n = 13) and 7% (n = 3) of cases, respectively. The same side effects have been reported in previous studies that performed sclerotherapy with anesthesia (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B24" ref-type="bibr">24</xref>). These data underscore the importance of care, mastery over the administration technique and professional experience in the treatment of OBVLs.</p><p>In the present study, OBVLs were more common on the lips, in women and in individuals with brown skin; mean age of the patients was approximately 53 years and most lesions were &#x02264; 1 cm in diameter. In conclusion, sclerotherapy with 5% EO is a minimally invasive, highly efficient treatment method that achieves the complete regression of lesions in up to 98% of cases of OBVLs. In addition, requires a smaller number of applications, has few side effects and is related to a high degree of patient satisfaction. Thus, the protocol used at our institution for more than 30 years for the treatment of OBVLs with 5% EO is safe and effective and favors a shorter treatment time.</p></sec></body><back><ack><title>Acknowledgement</title><p>Declared none.</p></ack><sec><title>Funding</title><p>This study was supported by Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES, Finance Code 001), Brazil. Silva HC is the recipient of a fellowship from CAPES.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest, financial or otherwise.</p></sec><notes><title>Institutional Review Board Statement</title><p>A retrospective study was conducted in agreement with the Declaration of Helsinki and received approval from the Human Research Ethics Committee of Federal University of the Jequitinhonha and Mucuri Valleys (approval certificate number: 5.960.085).</p></notes><notes><title>Author Contributions</title><p>Herberth Campos Silva: Study concept and design, data collection, data analysis, and writing the manuscript. Ana Cl&#x000e1;udia Oliveira Teles: data collection, data analysis. Gabriela Fonseca Rocha: data collection, data analysis, Esmeralda Maria da Silveira: data collection, data analysis, Delfheson Willya Douglas de Oliveira: data analysis, review the manuscript. Ana Terezinha Marques Mesquita: Conceptualization, review and editing the manuscript, approval of the final version of the manuscrip, supervision.</p></notes><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzano</surname><given-names>BR</given-names></name><name><surname>Premoli</surname><given-names>AM</given-names></name><name><surname>Santaella</surname><given-names>NG</given-names></name><name><surname>Ikuta</surname><given-names>CRS</given-names></name><name><surname>Rubira</surname><given-names>CMF</given-names></name><name><surname>Santos</surname><given-names>PSDS</given-names></name></person-group><article-title>Sclerotherapy as an esthetic indication in oral vascular malformations: A case series</article-title><source>An Bras Dermatol</source><year>2019</year><volume>94</volume><fpage>521</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31777351</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johann</surname><given-names>ACBR</given-names></name><name><surname>Aguiar</surname><given-names>MCF</given-names></name><name><surname>Carmo</surname><given-names>MAV</given-names></name><name><surname>Gomez</surname><given-names>RS</given-names></name><name><surname>Castro</surname><given-names>WH</given-names></name><name><surname>Mesquita</surname><given-names>RA</given-names></name></person-group><article-title>Sclerotherapy of benign oral vascular lesion with ethanolamine oleate: An open clinical trial with 30 lesions</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><year>2005</year><volume>100</volume><fpage>579</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16243243</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selim</surname><given-names>H</given-names></name><name><surname>Selim</surname><given-names>A</given-names></name><name><surname>Khachemoune</surname><given-names>A</given-names></name><name><surname>Metwally</surname><given-names>SA</given-names></name></person-group><article-title>Use of sclerosing agent in the management of oral and perioral hemangiomas: Review and case reports</article-title><source>Med Sci Monit</source><year>2007</year><volume>13</volume><fpage>114</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17767124</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haggstrom</surname><given-names>NA</given-names></name><name><surname>Drolet</surname><given-names>BA</given-names></name><name><surname>Baselga</surname><given-names>E</given-names></name><name><surname>Chamlin</surname><given-names>SL</given-names></name><name><surname>Garzon</surname><given-names>MC</given-names></name><name><surname>Horii</surname><given-names>KA</given-names></name></person-group><article-title>Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics</article-title><source>J Pediatr</source><year>2007</year><volume>150</volume><fpage>291</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17307549</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Kishishita</surname><given-names>S</given-names></name><name><surname>Tamaruya</surname><given-names>N</given-names></name><name><surname>Monobe</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name></person-group><article-title>Vascular malformations of the head and neck</article-title><source>Auris Nasus Larynx</source><year>2013</year><volume>40</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22534179</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name><name><surname>O-Ki</surname><given-names>K</given-names></name><name><surname>Cha</surname><given-names>SH</given-names></name><name><surname>Chang</surname><given-names>KH</given-names></name></person-group><article-title>Craniofacial cavernous venous malformations: percutaneous scleroterapy with use of ethanolamine oleate</article-title><source>J Vasc Interv Radiol</source><year>2002</year><volume>13</volume><fpage>475</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11997355</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemens</surname><given-names>RK</given-names></name><name><surname>Pfammatter</surname><given-names>T</given-names></name><name><surname>Meier</surname><given-names>TO</given-names></name><name><surname>Alomari</surname><given-names>AI</given-names></name><name><surname>Amann-Vesti</surname><given-names>BR</given-names></name></person-group><article-title>Vascular malformations revisited</article-title><source>Vasa</source><year>2015</year><volume>44</volume><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">25537054</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulliken</surname><given-names>JB</given-names></name><name><surname>Glowacki</surname><given-names>J</given-names></name></person-group><article-title>Hemangiomas and vascular malformations in infants and children: a classification based on endotelial characteristics</article-title><source>Plastic Reconstr Surg</source><year>1982</year><volume>69</volume><fpage>412</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">7063565</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowell</surname><given-names>C</given-names></name><name><surname>Verea Linares</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Monaghan</surname><given-names>A</given-names></name></person-group><article-title>Venous malformations of the head and neck: current concepts in management</article-title><source>Br J Oral Maxillofac Surg</source><year>2017</year><volume>55</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">27894790</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazos</surname><given-names>JP</given-names></name><name><surname>Piemonte</surname><given-names>ED</given-names></name><name><surname>Panico</surname><given-names>RL</given-names></name></person-group><article-title>Oral Varix: a review</article-title><source>Gerodontology</source><year>2015</year><volume>32</volume><fpage>82</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23992044</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>VA</given-names></name><name><surname>Lima</surname><given-names>NL</given-names></name><name><surname>Mesquita</surname><given-names>AT</given-names></name><name><surname>da Silveira</surname><given-names>EM</given-names></name><name><surname>Verli</surname><given-names>FD</given-names></name><name><surname>de Miranda</surname><given-names>JL</given-names></name></person-group><article-title>Intramuscular hemangioma in lip treated with sclerotherapy and surgery</article-title><source>Case Rep Dent</source><year>2011</year><volume>2011</volume><fpage>302451</fpage><pub-id pub-id-type="pmid">22567433</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baer</surname><given-names>AH</given-names></name><name><surname>Parmar</surname><given-names>HA</given-names></name><name><surname>DiPietro</surname><given-names>MA</given-names></name><name><surname>Kasten</surname><given-names>SJ</given-names></name><name><surname>Mukherji</surname><given-names>SK</given-names></name></person-group><article-title>Hemangiomas and vascular malformations of the head and neck: A simplified approach</article-title><source>Neuroimaging Clin N Am</source><year>2011</year><volume>21</volume><fpage>641</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21807316</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigaux</surname><given-names>N</given-names></name><name><surname>Viremouneix</surname><given-names>L</given-names></name><name><surname>Guibaud</surname><given-names>L</given-names></name><name><surname>Breton</surname><given-names>P</given-names></name></person-group><article-title>Malformations veineuses superficielles cervico-faciales. Mise au point [Head and neck superficial venous malformations]</article-title><source>Rev Stomatol Chir Maxillofac Chir Orale</source><year>2015</year><volume>116</volume><fpage>201</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26296277</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horbach</surname><given-names>SE</given-names></name><name><surname>Lokhorst</surname><given-names>MM</given-names></name><name><surname>Saeed</surname><given-names>P</given-names></name><name><surname>De Go&#x000fc;yon Matignon De Pontouraude</surname><given-names>CM</given-names></name><name><surname>Rothov&#x000e1;</surname><given-names>A</given-names></name><name><surname>van der Horst</surname><given-names>CM</given-names></name></person-group><article-title>Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents</article-title><source>J Plast J Plast Reconstr Aesthet Surg</source><year>2016</year><volume>69</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">26723834</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>DT</given-names></name><name><surname>Elias</surname><given-names>RA</given-names></name><name><surname>Santos-Silva</surname><given-names>AR</given-names></name><name><surname>Vargas</surname><given-names>PA</given-names></name><name><surname>Lopes</surname><given-names>MA</given-names></name></person-group><article-title>Benign oral vascular lesions treated by sclerotherapy with ethanolamine oleate: A retrospective study of 43 patients</article-title><source>Med Oral Patol Oral Cir Bucal</source><year>2018</year><volume>23</volume><fpage>180</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29476682</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoque</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>BK</given-names></name></person-group><article-title>Treatment of venous malformations with ethanolamine oleate: A descriptive study of 83 cases</article-title><source>Pediatr Surg Int</source><year>2011</year><volume>27</volume><fpage>527</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21290138</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>CN</given-names></name><name><surname>Ribeiro</surname><given-names>MC</given-names></name><name><surname>Abreu</surname><given-names>MH</given-names></name><name><surname>Grossmann</surname><given-names>SD</given-names></name><name><surname>Abreu</surname><given-names>LG</given-names></name><name><surname>Caldeira</surname><given-names>PC</given-names></name></person-group><article-title>What is the preferred concentration of ethanolamine oleate for sclerotherapyof oral vascular anomalies?</article-title><source>Med Oral Patol Oral Cir Bucal</source><year>2020</year><volume>25</volume><fpage>468</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32388528</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>WB</given-names></name><name><surname>Ribeiro</surname><given-names>AL</given-names></name><name><surname>Menezes</surname><given-names>SA</given-names></name><name><surname>de Jesus Viana Pinheiro</surname><given-names>J</given-names></name><name><surname>Alves-Junior</surname><given-names>S</given-names></name></person-group><article-title>Oral capillary hemangioma: A clinical protocol of diagnosis and treatment in adults</article-title><source>Oral Maxillofac Surg</source><year>2014</year><volume>18</volume><fpage>431</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24263242</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>PH</given-names></name><name><surname>Nunes</surname><given-names>LC</given-names></name><name><surname>Johann</surname><given-names>AC</given-names></name><name><surname>Aguiar</surname><given-names>MC</given-names></name><name><surname>Gomez</surname><given-names>RS</given-names></name><name><surname>Mesquita</surname><given-names>RA</given-names></name></person-group><article-title>Prevalence of oral hemangioma, vascular malformation and varix in a Brazilian population</article-title><source>Braz Oral Res</source><year>2007</year><volume>21</volume><fpage>40</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17384854</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanein</surname><given-names>AH</given-names></name><name><surname>Mulliken</surname><given-names>JB</given-names></name><name><surname>Fishman</surname><given-names>SJ</given-names></name><name><surname>Greene</surname><given-names>AK</given-names></name></person-group><article-title>Evaluation of terminology for vascular anomalies in current literature</article-title><source>Plast Reconstr Surg</source><year>2011</year><volume>127</volume><fpage>347</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21200229</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeevi</surname><given-names>I</given-names></name><name><surname>Chaushu</surname><given-names>G</given-names></name><name><surname>Alterman</surname><given-names>M</given-names></name><name><surname>Chaushu</surname><given-names>L</given-names></name></person-group><article-title>Sclerotherapy of Vascular Malformations in the Oral Cavity-Minimizing Postoperative Morbidity</article-title><source>Medicina</source><year>2020</year><volume>56</volume><fpage>254</fpage><pub-id pub-id-type="pmid">32456057</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>CNAO</given-names></name><name><surname>Ribeiro</surname><given-names>MC</given-names></name><name><surname>Amaral</surname><given-names>MBF</given-names></name><name><surname>Grossmann</surname><given-names>SMC</given-names></name><name><surname>Aguiar</surname><given-names>MCF</given-names></name><name><surname>Mesquita</surname><given-names>RA</given-names></name></person-group><article-title>Experience with 5% ethanolamine oleate for sclerotherapy of oral vascular anomalies: a cohort of 15 consecutive patients</article-title><source>J Craniomaxillofac Surg</source><year>2019</year><volume>47</volume><fpage>106</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30527382</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieden</surname><given-names>IJ</given-names></name></person-group><article-title>Special symposium: management of hemangiomas</article-title><source>Pediatric Dermatol</source><year>1997</year><volume>14</volume><fpage>57</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">9050768</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>JR</given-names></name><name><surname>Torriani</surname><given-names>MA</given-names></name><name><surname>Hosni</surname><given-names>ES</given-names></name><name><surname>D &#x000c1;vila</surname><given-names>OP</given-names></name><name><surname>Figueiredo</surname><given-names>PJ</given-names></name></person-group><article-title>Sclerotherapy for vascular malformations in the oral and maxillofacial region: treatment and follow-up of 66 lesions</article-title><source>J Oral Maxillofac Surg</source><year>2011</year><volume>69</volume><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">21272976</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraoka</surname><given-names>K</given-names></name><name><surname>Mota De Queiroz</surname><given-names>A</given-names></name><name><surname>Aparecida Marinho</surname><given-names>S</given-names></name><name><surname>Costa Pereira</surname><given-names>AA</given-names></name><name><surname>Costa Hanemann</surname><given-names>JA</given-names></name></person-group><article-title>Sclerotherapy with monoethanolamine oleate in benign oral vascular lesions</article-title><source>Minerva Stomatol</source><year>2012</year><volume>61</volume><fpage>31</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22274308</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashizume</surname><given-names>M</given-names></name><name><surname>Kitano</surname><given-names>S</given-names></name><name><surname>Yamaga</surname><given-names>H</given-names></name><name><surname>Sugimachi</surname><given-names>K</given-names></name></person-group><article-title>Haptoglobin to protect against renal damage from ethanolamine oleate sclerosant</article-title><source>Lancet</source><year>1988</year><volume>6</volume><fpage>340</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">2899760</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Koizumi</surname><given-names>Y</given-names></name><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>I</given-names></name><name><surname>Kubo</surname><given-names>Y</given-names></name></person-group><article-title>Sclerotherapy of hemangioma with late involution</article-title><source>Dermatol Surg</source><year>2003</year><volume>29</volume><fpage>668</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12786717</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariano</surname><given-names>FV</given-names></name><name><surname>Vargas</surname><given-names>PA</given-names></name><name><surname>Coletta</surname><given-names>RD</given-names></name><name><surname>Lopes</surname><given-names>MA</given-names></name></person-group><article-title>Sclerotherapy followed by surgery for the treatment of oral hemangioma: A report of two cases</article-title><source>Gen Dent</source><year>2011</year><volume>59</volume><fpage>121</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21903533</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Sung</surname><given-names>MW</given-names></name><name><surname>Roh</surname><given-names>JL</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name></person-group><article-title>Sclerotherapy for congenital lesions in the head and neck</article-title><source>Otolaryngol Head Neck Surg</source><year>2004</year><volume>131</volume><fpage>307</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15365552</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Masumoto</surname><given-names>T</given-names></name><name><surname>Okubo</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>O</given-names></name><name><surname>Kaji</surname><given-names>N</given-names></name><name><surname>Toquiota</surname><given-names>K</given-names></name></person-group><article-title>Hemangiomas in the face and extremities: MR-guided sclerotherapy-Optimization with monitoring of signal intensity changes in vivo</article-title><source>Radiology</source><year>2003</year><volume>226</volume><fpage>567</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12563156</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic characteristics, pain intensity and regression in the cases studied of OBVLs.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="3" colspan="2">Variable</th><th colspan="6" rowspan="1">Size</th><th rowspan="3" colspan="1">
<italic>p-value</italic>
</th></tr><tr><th colspan="2" rowspan="1">&#x02264; 1 cm</th><th colspan="2" rowspan="1">&#x0003e;1 and &#x02264; 2 cm</th><th colspan="2" rowspan="1">&#x0003e; 2 cm</th></tr><tr><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">81.3</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">75.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td rowspan="2" align="center" valign="middle" colspan="1">0.367</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">18.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">Skin color</td><td align="center" valign="middle" rowspan="1" colspan="1">Brown</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">59.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td rowspan="3" align="center" valign="middle" colspan="1">0.732</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">White</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">28.1</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Vascular lesions</td><td align="center" valign="middle" rowspan="1" colspan="1">Hemangioma/VM</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">96.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">87.5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0</td><td rowspan="2" align="center" valign="middle" colspan="1">0.471</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Oral varicosities</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1">Site</td><td align="center" valign="middle" rowspan="1" colspan="1">Lower lip</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">71.9</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">62.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td rowspan="6" align="center" valign="middle" colspan="1">0.034</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Upper lip</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tongue</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Palate</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Buccal mucosa</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr></tbody></table><table-wrap-foot><fn><p>VM: Vascular malformations.
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Data related to oral benign vascular lesions. Legends.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="3" colspan="2">Variable</th><th colspan="6" rowspan="1">Size</th><th rowspan="3" colspan="1">
<italic>et al.</italic>
</th></tr><tr><th colspan="2" rowspan="1">&#x02264; 1 cm</th><th colspan="2" rowspan="1">&#x0003e;1 and &#x02264; 2 cm</th><th colspan="2" rowspan="1">&#x0003e; 2 cm</th></tr><tr><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" colspan="1">Quantity of sclerosing agent</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264; 0.30 ml</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">65.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td rowspan="4" align="center" valign="middle" colspan="1">0.030</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e; 0.30 ml and &#x02264; 0.50 ml</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e; 0.50 ml and &#x02264;1.00 ml</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">18.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e; 1.00 ml</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1">Number of applications</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">31.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td rowspan="6" align="center" valign="middle" colspan="1">0.022</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">28.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6 or more</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">Interval between applications</td><td align="center" valign="middle" rowspan="1" colspan="1">2 weeks</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">68.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">75.0</td><td rowspan="3" align="center" valign="middle" colspan="1">0.033</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3 weeks</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4 or more weeks</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">18.8</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">75.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="5" align="center" valign="middle" colspan="1">Pain intensity</td><td align="center" valign="middle" rowspan="1" colspan="1">Absence of pain</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">18.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td rowspan="5" align="center" valign="middle" colspan="1">0.270</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mild (1-3 pain score)</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">34.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">75.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Moderate (4-5 pain score)</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Strong (6-7 pain score)</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">21.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Very strong (8-9 pain score)</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Regression of lesion</td><td align="center" valign="middle" rowspan="1" colspan="1">Complete</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">96.9</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">100.0</td><td rowspan="2" align="center" valign="middle" colspan="1">0.825</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Partial</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td></tr></tbody></table></table-wrap></floats-group></article>